Dr. David T. Rubin is Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. Dr. Rubin earned a medical degree with honors at The University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.
Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Physicians (ACP) and an active national member of the Crohn’s & Colitis Foundation (CCF), and is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator’s Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCF Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is currently the Chair-elect of the National Scientific Advisory Committee of the CCF. He is an Associate Editor of the journal Gastroenterology and Co-Editor of the ACG On-Line Educational Universe.
Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD), now in its 3rd edition, and an author or coauthor of many peer-reviewed articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the in progress ACG Guidelines for ulcerative colitis. His current research is in the area of progressive complications from uncontrolled inflammation, the doctor-patient relationship in IBD, and a variety of collaborative studies related to the microbiome and intestinal disease. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular twitter feed @IBDMD (>9500 followers). His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.
University of Chicago Pritzker School of Medicine
Chicago
Fellowship - Gastroenterology
2001
University of Chicago Pritzker School of Medicine
Chicago
Residency - Internal Medicine
1997
University of Chicago Pritzker School of Medicine
Chicago
MD
1994
University of Illinois
Urbana-Champaign
BS - Honors Biology
1990
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis.
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis. J Crohns Colitis. 2025 May 13.
PMID: 40355364
Global evolution of inflammatory bowel disease across epidemiologic stages.
Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Apr 30.
PMID: 40307548
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nat Rev Gastroenterol Hepatol. 2025 Apr 22.
PMID: 40263433
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
PMID: 38899786
Association of Bile Acid Diarrhea with Symptoms and Disease Activity in Crohn's Disease: Post-Hoc Clinical Trial Analysis of Serum 7a-hydroxy-4cholestern-3-one, C4, in Patients with Active Crohn's Disease.
Association of Bile Acid Diarrhea with Symptoms and Disease Activity in Crohn's Disease: Post-Hoc Clinical Trial Analysis of Serum 7a-hydroxy-4cholestern-3-one, C4, in Patients with Active Crohn's Disease. J Crohns Colitis. 2025 Apr 09.
PMID: 40202488
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
PMID: 40168091
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design.
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design. Lancet Gastroenterol Hepatol. 2025 Jun; 10(6):593-604.
PMID: 40187359
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31; 12(1).
PMID: 40164445
Hermansky-Pudlak Syndrome Complicated by Crohn's Disease and Hidradenitis Suppurativa: A Case of Multisystem Immune Dysregulation.
Hermansky-Pudlak Syndrome Complicated by Crohn's Disease and Hidradenitis Suppurativa: A Case of Multisystem Immune Dysregulation. ACG Case Rep J. 2025 Apr; 12(4):e01647.
PMID: 40165941
Exercise Therapies for Fibromyalgia Pain Catastrophizing: A Systematic Review and Comparative Analysis.
Exercise Therapies for Fibromyalgia Pain Catastrophizing: A Systematic Review and Comparative Analysis. Prim Care Companion CNS Disord. 2025 Mar 27; 27(2).
PMID: 40163350